Meeting
2024 ASCO Annual Meeting
J-TAIL-2: A prospective observational study of atezolizumab (atezo) combination therapy in patients (pts) with non-small cell lung cancer (NSCLC) in Japan.
Authors
Yasutaka Watanabe
Department of Thoracic Oncology, Saitama Cancer Center, Saitama, Japan
Yasutaka Watanabe , Makoto Nishio , Kadoaki Ohashi , Atsushi Osoegawa , Eiki Kikuchi , Hideharu Kimura , Yasushi Goto , Junichi Shimizu , Eisaku Miyauchi , Hiroshige Yoshioka , Ichiro Yoshino , Toshihiro Misumi , Masafumi Yamaguchi , Kouzou Yoshimori , Masahiro Seike , Hironori Yoshida , Kazumi Nishino , Asako Miwa , Misa Tanaka , Akihiko Gemma
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Metastatic
Track
Lung Cancer
Sub Track
Metastatic Non–Small Cell Lung Cancer
Clinical Trial Registration Number
NCT04501497
Citation
J Clin Oncol 42, 2024 (suppl 16; abstr 8573)
DOI
10.1200/JCO.2024.42.16_suppl.8573
Abstract #
8573
Poster Bd #
437
Abstract Disclosures
Similar Posters
Poster
2016 ASCO Annual Meeting
Phase III clinical trials of atezolizumab combined with chemotherapy in chemotherapy-naive patients with advanced NSCLC.
First Author: Vassiliki Papadimitrakopoulou
Poster
2019 ASCO Annual Meeting
IMpower150: Analysis of efficacy in patients (pts) with liver metastases (mets).
First Author: Mark A. Socinski
Poster
2022 ASCO Annual Meeting
A phase II study of AK112 (PD-1/VEGF bispecific) in combination with chemotherapy in patients with advanced non-small cell lung cancer.
First Author: Yuangyuan Zhao
Poster
2022 ASCO Annual Meeting
NEJ043: A phase 2 study of atezolizumab (atezo) plus bevacizumab (bev) plus carboplatin (carbo) plus paclitaxel (pac; ABCP) for previously treated patients with NSCLC harboring EGFR mutations (EGFRm).
First Author: Naoki Furuya